VC: Alder raises $40M



Alder raises $40M

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Alder Biopharmaceuticals
Bothell, WA

$40M
Third

Delphi Ventures and TPG Biotech

Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases. "

Bridge Laboratories
Gaithersburg, MD

$18M
Second

Unnamed

Bridge Laboratories will be expanding a toxicology lab in Beijing, China, and continue to grow U.S. operations. 

Novamed
China

$13.8M
Second

Fidelity Asia Ventures and Fidelity Biosciences

The company will use the proceeds to finance the in-licensing of new molecules for China, expand sales and distribution operations and strengthen medical research and development capacity.

Caprotec Bioanalytics
Germany

$8.8M
Round

Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors

The money will be used to further development and marketing of its platform technology for analyzing complex protein mixtures.

PeptImmune
Cambridge, MA

$8.2M
Fourth

New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital

The funding will be used to advance clinical development of Peptimmune's multiple sclerosis treatment, PI-2301.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.